Target intelligence / Profile preview

C10orf95 antisense RNA 1 (C10orf95-AS1)

Target
C10orf95-AS1
Molecular classification
Long non-coding RNA (lncRNA), Other (non-protein-coding gene)
01

Overview

C10orf95 antisense RNA 1 (C10orf95-AS1/RPARP-AS1) is a long non-coding RNA gene found on human chromosome 10. It is characterized by multiple transcript variants, none of which encode a protein[2]. Functionally, this lncRNA is upregulated in certain tumor types such as osteosarcoma and colorectal cancer, where it acts as an oncogene, enhancing cell proliferation, migration, and invasion while inhibiting apoptosis[1]. Mechanistically, it regulates lipid metabolism by modulating the Akt/mTOR pathway and downstream genes such as SCD1 and ADH1C, and affects epithelial-mesenchymal transition. Experimental data indicate that suppression (siRNA-mediated knockdown) of RPARP-AS1 in tumor cells can impede proliferation and promote apoptosis. Given its expression in a range of cancers and possible links to metabolic reprogramming, it is of emerging interest as a biomarker and novel therapeutic target. However, C10orf95-AS1 itself is a non-protein coding RNA, not a conventional receptor, enzyme, transporter, or transcription factor[2][1].

Other names
RPARP-AS1RPARP antisense RNA 1C10orf95-AS1
02

Mechanism of action

Not applicable (no drugs identified). However, experimental knockdown by siRNAs inhibits proliferation and induces apoptosis in cultured tumor cells[1].

03

Biological functions

Regulation of lipid metabolismPromotion of cell proliferationModulation of apoptosisRegulation of epithelial-mesenchymal transition (EMT)
04

Disease associations

Cancer (particularly osteosarcoma and colorectal cancer)Possible association with non-alcoholic fatty liver disease (bioinformatic evidence; not experimentally validated)
05

Safety considerations

None specifically reported in current medical or preclinical literature. However, as a potential therapeutic target in cancer, non-specific modulation may carry risks inherent to RNA-targeting approaches.
06

Biomarkers

Upregulation of C10orf95-AS1/RPARP-AS1 is associated with tumor progression and poor prognosis in osteosarcoma and colorectal cancer[1]

Beyond the preview

Go deeper on C10orf95 antisense RNA 1 (C10orf95-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C10orf95 antisense RNA 1 (C10orf95-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call